EDIT
|Editas Medicine Inc
NASDAQ
USD 2.35
+0.21|+9.81%
Current Price
USD 2.35
Change
+USD 0.21 (9.81%)
P/E Ratio
Dividend Yield
Market Cap
159.89M
Volume
3.58M
Open
USD 2.17
Previous Close
USD 2.14
52-Week High
USD 6.22
52-Week Low
USD 0.91
About Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in No...
Sector:Healthcare
Industry:Biotechnology
CEO:Dr. Gilmore O'Neill M.D.
Employees:246
Headquarters:Cambridge, USA
Website:www.editasmedicine.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions